346 PATENT ABSTRACTS

colorimetric analysis of the colored quinone- type compound produced. This conversion may take place in the presence of an oxidizing agent, such as a copper (I1) salt, and/or a base, such as ammonia. A diagnostic kit to allow the routine use of the above method is also provided, in one embodiment of the kit, it comprises, (a) an aryl acylamidase, in solution or on a solid support, (b) an organic compound suitable for the conver- sion of the aniline to an indamine, an indophenol or an indoaniline, preferably in solution, and (c) a base, preferably in solution. The kit may fur- ther comprise an oxidizing agent, again preferably in solution. The above method of analysis and diagnostic kit may be particularly useful in the estimation of anilide drugs, such as paracetamol, dissolved in biological fluids.

4414326

D I A G N O S T I C A G E N T S

Jack M Goldberg

Diagnostic agents are described for determining high density lipoprotein cholesterol in body fuids such as serum or plasma. One is an en- zymatic reagent for quantitative analysis for cholesterol composed of cholesterol oxidase, cholesterol esterase, peroxidase, 4-amino- antipyrine, a phenol or phenol derivative, a sur- factant, such as sodium cholate and a polyglycol of molecular weight from about 190 to 1000, buf- fered to pH 5.5 to 7.8 in water. The other is a single, stable precipitating agent for lipoproteins in body fluids, comprising a bivalent metal salt of a monobasic acid, such as magnesium chloride and a water-soluble polyanion, such as sodium phosphotungstate in water at pH 5 to 8.

4414324

I M M U N O A S S A Y M E T H O D A N D A P P A R A T U S

Robert L Stout assigned to BMA Laboratory Services Inc

An improved immunoassay sample determina- tion process for determining the presence of a

component of an antigen-antibody reaction in a sample is disclosed which substantially eliminates non-specific interactions between the sample and the reaction vessel wall surfaces during the antigen-antibody reaction, to thereby greatly increase the accuracy of the process. In practice, a site-deactivating medium such as an animal- or vegetable-derived total biological fluid or extract (e.g., plasma or gelatin) is cova- lently bound to the vessel wall surfaces for deac- tivation purposes. In preferred forms the process is solid-state, wherein one of the components of the antigen-antibody reaction is coupled cova- lently to the coating medium, and a reaction mix- ture fraction including the sample being determined and the other component which has been labeled, for instance by means of a colorimetrically active enzyme.

4414150

H Y B R I D H U M A N L E U K O C Y T E I N T E R F E R O N S

David Goeddel assigned to Genentech Inc

Disclosed herein are methods and means of microbially preparing novel human hybrid leukocyte interferons, useful in the treatment of viral and neoplastic diseases, by DNA recom- bination of parental interferon genes, taking ad- vantage of common restriction endonuclease cleavage sites therein and in carrier expression plasmkis.

4414148

A N T I - C A N C E R D R U G S F O R T H E T R E A T M E N T O F M E L A N O M A S

A N D M E T H O D F O R P R E P A R I N G T H E R E O F

Franz K Jansen, Pierr Gros, Castries, France as- signed to Sanofi

The present invention relates to drugs useful in particular for the treatment of melanomas, characterized in that they contain an active sub- stance which is a molecule in which the chain A of ricin is associated, by a covalent bond of dis- ulfide type, with a human antimelanoma antibody.